Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo for Allopurinol Clear all
Completed Phase 2 Interventional Results available

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

NCT00819585
View directory record Official record
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout

NCT01129648
View directory record Official record
Conditions
Gout
Interventions
Placebo, Allopurinol, BCX4208
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Scottsdale, Arizona • Irvine, California • South Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2012 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

NCT01407874
View directory record Official record
Conditions
Gout, Hyperuricemia, Arthritis, Joint Disease, Renal Insufficiency
Interventions
Placebo, Ulodesine (BCX4208) 5 mg, Ulodesine (BCX4208) 10 mg
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Mobile, Alabama • Peoria, Arizona • Irvine, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 25, 2026, 6:53 PM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

NCT03226899
View directory record Official record
Conditions
Gout, Chronic Kidney Disease (CKD)
Interventions
Lesinurad, XOI, Placebo, colchicine, corticosteroids
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes

NCT00116207
View directory record Official record
Conditions
Diabetic Autonomic Neuropathy
Interventions
ORAL ANTIOXIDANT
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Allopurinol Combination Study

NCT01001338
View directory record Official record
Conditions
Gout
Interventions
RDEA594, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01510158
View directory record Official record
Conditions
Gout
Interventions
Lesinurad, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
165
States / cities
Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 139 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

NCT02956278
View directory record Official record
Conditions
Chronic Gout, Hyperuricemia
Interventions
Allopurinol, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 25, 2026, 6:53 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Allopurinol for Renal Transplant Associated Hypertension in Children

NCT00288171
View directory record Official record
Conditions
Hypertension, Renal Transplant
Interventions
Placebo, Allopurinol
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 2Phase 3 Interventional

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

NCT05818085
View directory record Official record
Conditions
Gout
Interventions
ABP-671, Allopurinol, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
19 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Tempe, Arizona • Tuscon, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol

NCT01451645
View directory record Official record
Conditions
Intercritical Gout
Interventions
Colchicine (Colcrys®), placebo, allopurinol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Alabaster, Alabama • Mesa, Arizona • Upland, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

NCT01399008
View directory record Official record
Conditions
Gout
Interventions
Arhalofenate, Allopurinol, Colchicine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
16
States / cities
Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

Allopurinol Add-on Treatment for Refractory Mania

NCT00643123
View directory record Official record
Conditions
Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
Interventions
Allopurinol, Placebo
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 4 Interventional

Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout

NCT01310673
View directory record Official record
Conditions
Gout, Gout Acute
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

NCT05586971
View directory record Official record
Conditions
Gout, Hyperuricemia, Gout Flare, Tophi
Interventions
Tigulixostat, Allopurinol, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
124
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones

NCT01077284
View directory record Official record
Conditions
Hyperuricosuria, Kidney Stones
Interventions
Febuxostat, Allopurinol, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

NCT00829829
View directory record Official record
Conditions
Intercritical Gout
Interventions
Placebo, Rilonacept 80 mg, Rilonacept 160 mg
Other · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
67
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels

NCT00987415
View directory record Official record
Conditions
Heart Failure, Elevated Serum Uric Acid
Interventions
allopurinol, sugar pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 25, 2026, 6:53 PM EDT
Terminated Phase 4 Interventional Results available

Xanthine Oxidase Inhibition in Renal Transplant Recipients

NCT01332799
View directory record Official record
Conditions
Complications of Renal Transplant
Interventions
allopurinol or placebo, Placebo
Drug · Other
Lead sponsor
Roberto S Kalil
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

NCT00856206
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo
Biological · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
77
States / cities
Alabaster, Alabama • Mesa, Arizona • Burbank, California + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Uric Acid and Hypertension in African Americans

NCT00241839
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions
Allopurinol, Placebo, Chlorthalidone, Potassium chloride
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol

NCT01265264
View directory record Official record
Conditions
Gout, Hyperuricemia, Arthritis, Joint Disease
Interventions
ulodesine, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
54
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Study Utilizing Rilonacept in Gout Exacerbations

NCT00855920
View directory record Official record
Conditions
Acute Gout Flare
Interventions
Rilonacept, Indomethacin, Placebo (for Indomethacin), Placebo (for Rilonacept)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 25, 2026, 6:53 PM EDT